IgG-cleaving endopeptidase enables in vivo gene therapy in the presence of anti-AAV neutralizing antibodies

Journal: Nature Medicine

Published: 2020-06-01

DOI: 10.1038/s41591-020-0911-7

Affiliations: 4

Authors: 22

Go to article
Institutions Share
Spark Therapeutics, Inc., United States of America (USA) 0.48
Integrated Genetic Approaches in Therapeutic Discovery for Rare Diseases (INTEGRARE), France 0.39
Cordelier Research Center (CRC), France 0.14

Return

Except where otherwise noted © 2021 Springer Nature Limited. All Rights Reserved.
partner of AGORA, HINARI, OARE, INASP, ORCID, CrossRef and COUNTER